Could a gut zapping procedure free diabetics from insulin?

NCT ID NCT06655740

Ongoing Disease control Sponsor: Aqua Medical, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests a device that uses radiofrequency vapor to ablate (remove) a thin layer of the duodenum (the first part of the small intestine) in 16 adults with type 2 diabetes who need insulin. The goal is to see if this procedure, with or without the drug semaglutide, is safe and can help patients stop insulin therapy while keeping blood sugar under control. Participants will be followed for about 6 months to check safety and whether they remain insulin-free with an HbA1c of 7.5% or lower.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RF vapor ablation device and semaglutide
What this could lead to: If successful, this could offer a non-drug procedure to help some type 2 diabetes patients stop insulin injections, possibly combined with semaglutide.
What could go wrong: This is a very small early pilot study (16 people) with no control group. The procedure involves ablating part of the gut, which carries risks like bleeding or infection. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

Clinica Colonial

Santiago, Chile

More trials for these conditions

Other studies related to the condition(s) this trial covers.